Gilead Sciences, Inc. (GILD) PB Ratio: 6.69
Is Gilead Sciences, Inc.’s P/B ratio high or low?
Gilead Sciences, Inc.'s P/B ratio of 6.69 is 25% above its 5-year average of 5.35, around the middle of its 5-year range (3.47–9.07).
The P/B ratio for Gilead Sciences, Inc. (GILD) is 6.69. It is below its 12-month average by 10.51% (7.48).
GILD PB Ratio Chart
GILD Average PB Ratio Chart
GILD Current vs Average PB Ratio Chart
GILD PB Ratio Metrics
PB RATIO
6.69
PB RATIO AVG TTM
7.48
PB RATIO AVG 3Y
6.02
PB RATIO AVG 5Y
5.35
PB RATIO AVG 10Y
5.00
PB RATIO AVG 15Y
6.21
PB RATIO AVG 20Y
7.22
CURRENT VS TTM AVG
-10.51%
CURRENT VS 3Y AVG
+11.14%
CURRENT VS 5Y AVG
+25.06%
CURRENT VS 10Y AVG
+33.76%
CURRENT VS 15Y AVG
+7.71%
CURRENT VS 20Y AVG
-7.28%
GILD Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | — | 6.69 | 7.48 | 6.02 | 5.35 |
| Abbott Laboratories (ABT) | $158.94B | 3.06 | 4.08 | 4.66 | 5.10 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 8.78 | 10.31 | 10.61 | 9.89 |
| Pfizer Inc. (PFE) | $146.48B | 1.63 | 1.63 | 1.71 | 2.36 |
| Danaher Corporation (DHR) | $133.37B | 2.53 | 2.82 | 3.16 | 3.48 |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 3.55 | 3.75 | 4.22 | 4.73 |
| Amgen Inc. (AMGN) | $185.96B | 20.40 | 21.35 | 23.63 | 31.87 |
| CVS Health Corporation (CVS) | $123.84B | 1.60 | 1.29 | 1.17 | 1.37 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 5.75 | 5.81 | 5.34 | 4.99 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 5.90 | 6.42 | 6.73 | 6.44 |
P/B vs. its own history
At 6.69, P/B is in its normal range — richer than 55% of its 20-year range.
20-year low
3.46
median
5.87
20-year high
21.22
Book Value Analysis
P/B Ratio
6.69
Market Price / Book Value per Share
Gilead Sciences, Inc. PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. PB Ratio FAQ
- What is the P/B ratio for Gilead Sciences, Inc. (GILD)?
- The P/B ratio for GILD stock is 6.69.
- Is Gilead Sciences, Inc.'s P/B ratio high or low?
- Gilead Sciences, Inc.'s P/B ratio of 6.69 is 25% above its 5-year average of 5.35, around the middle of its 5-year range (3.47–9.07).
- What is the TTM average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The TTM average P/B ratio for GILD stock is 7.48.
- What is the 3Y average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The 3Y average P/B ratio for GILD stock is 6.02.
- What is the 5Y average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The 5Y average P/B ratio for GILD stock is 5.35.
- What is the 10Y average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The 10Y average P/B ratio for GILD stock is 5.00.
- What is the 15Y average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The 15Y average P/B ratio for GILD stock is 6.21.
- What is the 20Y average P/B ratio for Gilead Sciences, Inc. (GILD)?
- The 20Y average P/B ratio for GILD stock is 7.22.
Gilead Sciences, Inc. PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-09 | 6.69 |
| 2026-06-08 | 6.83 |
| 2026-06-05 | 6.89 |
| 2026-06-04 | 6.89 |
| 2026-06-03 | 6.88 |
| 2026-06-02 | 6.80 |
| 2026-06-01 | 6.99 |
| 2026-05-29 | 7.17 |
| 2026-05-28 | 7.26 |
| 2026-05-27 | 7.13 |
| 2026-05-26 | 7.13 |
| 2026-05-22 | 7.17 |
| 2026-05-21 | 6.96 |
| 2026-05-20 | 6.97 |
| 2026-05-19 | 6.96 |
| 2026-05-18 | 6.91 |
| 2026-05-15 | 6.91 |
| 2026-05-14 | 7.04 |
| 2026-05-13 | 7.10 |
| 2026-05-12 | 7.20 |
| 2026-05-11 | 7.12 |
| 2026-05-08 | 7.00 |
| 2026-05-07 | 7.15 |
| 2026-05-06 | 7.55 |
| 2026-05-05 | 7.39 |
| 2026-05-04 | 7.35 |
| 2026-05-01 | 7.29 |
| 2026-04-30 | 7.25 |
| 2026-04-29 | 7.14 |
| 2026-04-28 | 7.16 |
| 2026-04-27 | 7.08 |
| 2026-04-24 | 7.22 |
| 2026-04-23 | 7.40 |
| 2026-04-22 | 7.36 |
| 2026-04-21 | 7.38 |
| 2026-04-20 | 7.53 |
| 2026-04-17 | 7.63 |
| 2026-04-16 | 7.68 |
| 2026-04-15 | 7.74 |
| 2026-04-14 | 7.78 |
| 2026-04-13 | 7.70 |
| 2026-04-10 | 7.70 |
| 2026-04-09 | 7.87 |
| 2026-04-08 | 7.84 |
| 2026-04-07 | 7.69 |
| 2026-04-06 | 7.76 |
| 2026-04-02 | 7.74 |
| 2026-04-01 | 7.77 |
| 2026-03-31 | 7.72 |
| 2026-03-30 | 7.55 |
| 2026-03-27 | 7.44 |
| 2026-03-26 | 7.58 |
| 2026-03-25 | 7.66 |
| 2026-03-24 | 7.65 |
| 2026-03-23 | 7.61 |
| 2026-03-20 | 7.60 |
| 2026-03-19 | 7.82 |
| 2026-03-18 | 7.83 |
| 2026-03-17 | 8.00 |
| 2026-03-16 | 8.04 |
| 2026-03-13 | 8.03 |
| 2026-03-12 | 8.04 |
| 2026-03-11 | 8.09 |
| 2026-03-10 | 8.23 |
| 2026-03-09 | 8.12 |
| 2026-03-06 | 7.97 |
| 2026-03-05 | 8.04 |
| 2026-03-04 | 8.21 |
| 2026-03-03 | 8.19 |
| 2026-03-02 | 8.31 |
| 2026-02-27 | 8.25 |
| 2026-02-26 | 7.96 |
| 2026-02-25 | 8.15 |
| 2026-02-24 | 8.18 |
| 2026-02-23 | 8.72 |
| 2026-02-20 | 8.81 |
| 2026-02-19 | 8.80 |
| 2026-02-18 | 8.89 |
| 2026-02-17 | 9.04 |
| 2026-02-13 | 9.02 |
| 2026-02-12 | 8.84 |
| 2026-02-11 | 9.07 |
| 2026-02-10 | 8.57 |
| 2026-02-09 | 8.83 |
| 2026-02-06 | 8.88 |
| 2026-02-05 | 8.70 |
| 2026-02-04 | 8.51 |
| 2026-02-03 | 8.34 |
| 2026-02-02 | 8.32 |
| 2026-01-30 | 8.26 |
| 2026-01-29 | 8.12 |
| 2026-01-28 | 8.13 |
| 2026-01-27 | 8.21 |
| 2026-01-26 | 8.02 |
| 2026-01-23 | 7.91 |
| 2026-01-22 | 7.63 |
| 2026-01-21 | 7.52 |
| 2026-01-20 | 7.23 |
| 2026-01-16 | 7.27 |
| 2026-01-15 | 7.06 |
| 2026-01-14 | 7.22 |
| 2026-01-13 | 7.09 |
| 2026-01-12 | 7.14 |
| 2026-01-09 | 7.05 |
| 2026-01-08 | 7.03 |
| 2026-01-07 | 7.24 |
| 2026-01-06 | 7.07 |
| 2026-01-05 | 6.89 |
| 2026-01-02 | 7.08 |
| 2025-12-31 | 7.15 |
| 2025-12-30 | 7.17 |
| 2025-12-29 | 7.27 |
| 2025-12-26 | 7.26 |
| 2025-12-24 | 7.32 |
| 2025-12-23 | 7.29 |
| 2025-12-22 | 7.23 |
| 2025-12-19 | 7.24 |
| 2025-12-18 | 7.07 |
| 2025-12-17 | 7.07 |
| 2025-12-16 | 6.92 |
| 2025-12-15 | 6.97 |
| 2025-12-12 | 7.01 |
| 2025-12-11 | 7.17 |
| 2025-12-10 | 7.06 |
| 2025-12-09 | 6.95 |
| 2025-12-08 | 7.06 |
| 2025-12-05 | 7.06 |
| 2025-12-04 | 7.14 |
| 2025-12-03 | 7.28 |
| 2025-12-02 | 7.21 |
| 2025-12-01 | 7.24 |
| 2025-11-28 | 7.33 |
| 2025-11-26 | 7.42 |
| 2025-11-25 | 7.40 |
| 2025-11-24 | 7.29 |
| 2025-11-21 | 7.37 |
| 2025-11-20 | 7.28 |
| 2025-11-19 | 7.46 |
| 2025-11-18 | 7.40 |
| 2025-11-17 | 7.22 |
| 2025-11-14 | 7.28 |
| 2025-11-13 | 7.29 |
| 2025-11-12 | 7.18 |
| 2025-11-11 | 7.14 |
| 2025-11-10 | 6.88 |
| 2025-11-07 | 6.92 |
| 2025-11-06 | 7.87 |
| 2025-11-05 | 7.82 |
| 2025-11-04 | 7.85 |
| 2025-11-03 | 7.79 |
| 2025-10-31 | 7.64 |
| 2025-10-30 | 7.55 |
| 2025-10-29 | 7.56 |
| 2025-10-28 | 7.52 |
| 2025-10-27 | 7.68 |
| 2025-10-24 | 7.71 |
| 2025-10-23 | 7.70 |
| 2025-10-22 | 7.75 |
| 2025-10-21 | 7.91 |
| 2025-10-20 | 7.85 |
| 2025-10-17 | 7.83 |
| 2025-10-16 | 7.52 |
| 2025-10-15 | 7.55 |
| 2025-10-14 | 7.56 |
| 2025-10-13 | 7.54 |
| 2025-10-10 | 7.47 |
| 2025-10-09 | 7.45 |
| 2025-10-08 | 7.54 |
| 2025-10-07 | 7.45 |
| 2025-10-06 | 7.24 |
| 2025-10-03 | 7.19 |
| 2025-10-02 | 7.05 |
| 2025-10-01 | 7.09 |
| 2025-09-30 | 7.08 |
| 2025-09-29 | 7.18 |
| 2025-09-26 | 7.15 |
| 2025-09-25 | 7.08 |
| 2025-09-24 | 7.25 |
| 2025-09-23 | 7.30 |
| 2025-09-22 | 7.18 |
| 2025-09-19 | 7.28 |
| 2025-09-18 | 7.25 |
| 2025-09-17 | 7.16 |
| 2025-09-16 | 7.07 |
| 2025-09-15 | 7.18 |
| 2025-09-12 | 7.31 |
| 2025-09-11 | 7.52 |
| 2025-09-10 | 7.35 |
| 2025-09-09 | 7.38 |
| 2025-09-08 | 7.39 |
| 2025-09-05 | 7.34 |
| 2025-09-04 | 7.19 |
| 2025-09-03 | 7.21 |
| 2025-09-02 | 7.19 |
| 2025-08-29 | 7.21 |
| 2025-08-28 | 7.18 |
| 2025-08-27 | 7.27 |
| 2025-08-26 | 7.32 |
| 2025-08-25 | 7.28 |
| 2025-08-22 | 7.32 |
| 2025-08-21 | 7.41 |
| 2025-08-20 | 7.57 |
| 2025-08-19 | 7.53 |
| 2025-08-18 | 7.53 |
| 2025-08-15 | 7.55 |
| 2025-08-14 | 7.59 |
| 2025-08-13 | 7.66 |
| 2025-08-12 | 7.66 |
| 2025-08-11 | 7.68 |
| 2025-08-08 | 7.62 |
| 2025-08-07 | 7.03 |
| 2025-08-06 | 7.25 |
| 2025-08-05 | 7.39 |
| 2025-08-04 | 7.52 |
| 2025-08-01 | 7.44 |
| 2025-07-31 | 7.38 |
| 2025-07-30 | 7.54 |
| 2025-07-29 | 7.51 |
| 2025-07-28 | 7.43 |
| 2025-07-25 | 7.63 |
| 2025-07-24 | 7.44 |
| 2025-07-23 | 7.46 |
| 2025-07-22 | 7.24 |
| 2025-07-21 | 7.11 |
| 2025-07-18 | 7.11 |
| 2025-07-17 | 7.15 |
| 2025-07-16 | 7.22 |
| 2025-07-15 | 7.17 |
| 2025-07-14 | 7.36 |
| 2025-07-11 | 7.20 |
| 2025-07-10 | 7.53 |
| 2025-07-09 | 7.44 |
| 2025-07-08 | 7.30 |
| 2025-07-07 | 7.34 |
| 2025-07-03 | 7.34 |
| 2025-07-02 | 7.33 |
| 2025-07-01 | 7.34 |
| 2025-06-30 | 7.28 |
| 2025-06-27 | 7.27 |
| 2025-06-26 | 7.07 |
| 2025-06-25 | 6.96 |
| 2025-06-24 | 7.04 |
| 2025-06-23 | 6.98 |
| 2025-06-20 | 7.13 |
| 2025-06-18 | 7.10 |
| 2025-06-17 | 7.10 |
| 2025-06-16 | 7.28 |
| 2025-06-13 | 7.23 |
| 2025-06-12 | 7.36 |
| 2025-06-11 | 7.18 |
| 2025-06-10 | 7.23 |
| 2025-06-09 | 7.42 |
| 2025-06-06 | 7.39 |
| 2025-06-05 | 7.26 |
| 2025-06-04 | 7.16 |
| 2025-06-03 | 7.18 |
| 2025-06-02 | 7.16 |
| 2025-05-30 | 7.23 |
| 2025-05-29 | 7.30 |
| 2025-05-28 | 7.12 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day